fr
Article scientifique
Anglais

A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients

Publié dansAntiviral therapy, vol. 10, no. 6, p. 761-767
Date de publication2005
Résumé

OBJECTIVE: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. DESIGN: Two-hundred antiretroviral-naive patients with CD4+ cell counts between 200-350 at screening were enrolled in this open-label 24week study. METHODS: Patients were followed up every 8 weeks for CD4+ cells, HIV RNA, and clinical and laboratory toxicities. RESULTS: Two-hundred patients were enrolled with median baseline CD4+ cell count of 267 cells/microl and HIV RNA 50 118 (4.7 log10) copies/mi. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4+ cell count of 122 cells/microl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 (P = 0.957) or absolute HIV RNA at week 24 (P = 0.77). CONCLUSION: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials.

Mots-clés
  • Adult
  • Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use
  • Antiretroviral Therapy, Highly Active/ adverse effects
  • CD4 Lymphocyte Count
  • Drug Therapy, Combination
  • Female
  • HIV Infections/ drug therapy/virology
  • HIV-1/drug effects
  • Humans
  • Male
  • Prospective Studies
  • RNA, Viral/blood
  • Reverse Transcriptase Inhibitors/administration & dosage/adverse
  • Effects/ therapeutic use
  • Ritonavir/administration & dosage/adverse effects/therapeutic use
  • Saquinavir/administration & dosage/adverse effects/therapeutic use
  • Thailand
  • Treatment Outcome
Citation (format ISO)
ANANWORANICH, Jintanat et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. In: Antiviral therapy, 2005, vol. 10, n° 6, p. 761–767.
Fichiers principaux (1)
Article
accessLevelRestricted
Identifiants
ISSN du journal1359-6535
459vues
0téléchargements

Informations techniques

Création21.06.2010 10:23:05
Première validation21.06.2010 10:23:05
Heure de mise à jour14.03.2023 15:42:37
Changement de statut14.03.2023 15:42:37
Dernière indexation12.02.2024 18:26:35
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack